Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab vs placebo in men with osteoporosis
2013-005551-32Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteoporosis comparing Romosozumab with Placebo (2 arms). Primary endpoint: Percent change from baseline in lumbar spine BMD at month 12. Started May 2014; status: completed.
02
Drugs
romosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2013-005551-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005551-32.